Holen Sie sich die Stockscreener-App
2.73
1.09%
-0.03
Handel nachbörslich:
2.70
-0.03
-1.10%
Schlusskurs vom Vortag:
$2.76
Offen:
$2.79
24-Stunden-Volumen:
944.77K
Relative Volume:
0.61
Marktkapitalisierung:
$184.51M
Einnahmen:
$6.96M
Nettoeinkommen (Verlust:
$-46.51M
KGV:
-15.91
EPS:
-0.1716
Netto-Cashflow:
$-37.99M
1W Leistung:
-9.60%
1M Leistung:
-31.92%
6M Leistung:
-82.60%
1J Leistung:
-71.56%
1-Tages-Spanne:
$2.36
$2.79
1-Wochen-Bereich:
$2.36
$3.11
52-Wochen-Spanne:
$2.36
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Vergleichen Sie CATX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.73 | 184.51M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-01 | Eingeleitet | Wedbush | Outperform |
| 2024-09-25 | Eingeleitet | Truist | Buy |
| 2024-07-25 | Eingeleitet | BofA Securities | Buy |
| 2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
CATX stock touches 52-week low at $2.6 amid market fluctuations - Investing.com
Vontobel Holding Ltd. Invests $51,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (CATX) Stock Price, News & Analysis - MarketBeat
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - The Manila Times
Perspective Therapeutics, Inc. to Report Full Year 2024 Financial Results and Business Update on March 26, 2025 - Nasdaq
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - GlobeNewswire Inc.
Perspective Therapeutics (NYSE:CATX) vs. Titan Medical (NASDAQ:TMDIF) Head to Head Analysis - Defense World
SG Americas Securities LLC Has $83,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Examining the Potential Price Growth of Perspective Therapeutics Inc (CATX) - Knox Daily
Cantor Fitzgerald Estimates CATX FY2024 Earnings - MarketBeat
Ratios Uncovered: Breaking Down Perspective Therapeutics Inc (CATX)’s Trailing Twelve Months Metrics - The Dwinnex
Perspective Therapeutics (NYSE:CATX) Upgraded at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Predicts CATX FY2024 Earnings - Defense World
Amicus Therapeutics Inc Inc. (FOLD) Price Performance: A Technical Analysis Perspective - The InvestChronicle
The radiopharma landscape takes shape in neuroendocrine tumors - BioCentury
Perspective Therapeutics (NYSE:CATX) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Its Stock Has Paid Off Big Time For Perspective Therapeutics Inc - SETE News
CATX overperforms with a 1.52 increase in share price - US Post News
ForexTV | Small Business Resources - ForexTV.com
Perspective Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Precision Oncology Pioneer Perspective Therapeutics Takes Center Stage at Oppenheimer and B. Riley Conferences - StockTitan
Analysts review Perspective Therapeutics Inc’s rating - Knox Daily
Achilles Therapeutics Plc ADR Inc. (ACHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Analyzing Endeavor Group Holdings Inc (EDR) After Recent Trading Activity - Knox Daily
JPMorgan Chase & Co. Has $333,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
JNM Publishes Guideline for FAP PET - Imaging Technology News
Lucid raises Perspective Therapeutics stock target to $20 By Investing.com - Investing.com Australia
Lucid raises Perspective Therapeutics stock target to $20 - Investing.com India
Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from Wedbush - MarketBeat
Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars - AOL
Perspective Therapeutics, Inc. Continues to Pursue Dose Escalation of [212Pb) Vmt-A-Net in Its Ongoing Phase 1/2A Clinical Trial Based on Updated Interim Data Presented At the 2025 Asco Gastrointestinal Cancers Symposium - Marketscreener.com
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium - The Manila Times
Perspective's Cancer Drug Shows Promising Results in Phase 1/2a Trial, Zero Toxicity Issues - StockTitan
Cantor Fitzgerald Forecasts CATX FY2025 Earnings - Defense World
Brokers Offer Predictions for CATX FY2025 Earnings - MarketBeat
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 - The Manila Times
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 - The Manila Times
Nuclear Medicine Market Size & Global Growth Report [2032] - Fortune Business Insights
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Financial Survey: Beyond Air (NASDAQ:XAIR) versus Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Perspective Therapeutics' (CATX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Perspective Therapeutics provides business updates, strategic priorities - Yahoo Finance
Perspective Therapeutics (NYSE:CATX) Receives Outperform Rating from Wedbush - Defense World
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Perspective Therapeutics Advances Cancer Pipeline with $227.8M Cash Runway Through 2026 - StockTitan
Barclays PLC Has $1.52 Million Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
0.57%
Kapitalisierung:
|
Volumen (24h):